Molecular Templates Inc
NASDAQ:MTEM
Molecular Templates Inc
Revenue
Molecular Templates Inc
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Molecular Templates Inc
NASDAQ:MTEM
|
Revenue
$57.3m
|
CAGR 3-Years
45%
|
CAGR 5-Years
34%
|
CAGR 10-Years
16%
|
|
Abbvie Inc
NYSE:ABBV
|
Revenue
$54.3B
|
CAGR 3-Years
6%
|
CAGR 5-Years
11%
|
CAGR 10-Years
11%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Revenue
$27.5B
|
CAGR 3-Years
2%
|
CAGR 5-Years
4%
|
CAGR 10-Years
7%
|
|
Amgen Inc
NASDAQ:AMGN
|
Revenue
$28.2B
|
CAGR 3-Years
4%
|
CAGR 5-Years
3%
|
CAGR 10-Years
4%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Revenue
$9.9B
|
CAGR 3-Years
17%
|
CAGR 5-Years
26%
|
CAGR 10-Years
23%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Revenue
$13.1B
|
CAGR 3-Years
16%
|
CAGR 5-Years
14%
|
CAGR 10-Years
20%
|
See Also
What is Molecular Templates Inc's Revenue?
Revenue
57.3m
USD
Based on the financial report for Dec 31, 2023, Molecular Templates Inc's Revenue amounts to 57.3m USD.
What is Molecular Templates Inc's Revenue growth rate?
Revenue CAGR 10Y
16%
Over the last year, the Revenue growth was 190%. The average annual Revenue growth rates for Molecular Templates Inc have been 45% over the past three years , 34% over the past five years , and 16% over the past ten years .